Illumina, Inc. (ETR:ILU)

Market Cap	17.32B
Revenue (ttm)	3.67B
Net Income (ttm)	601.21M
Shares Out	n/a
EPS (ttm)	3.81
PE Ratio	28.81
Forward PE	26.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	142
Average Volume	533
Open	112.18
Previous Close	111.70
Day's Range	112.06 - 112.86
52-Week Range	62.00 - 143.78
Beta	1.13
RSI	74.37
Earnings Date	Feb 6, 2026

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1998
• Employees: 9,030
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ILU

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD